KR20240075952A - Fgfr 억제제 및 이의 사용 방법 - Google Patents

Fgfr 억제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240075952A
KR20240075952A KR1020247013425A KR20247013425A KR20240075952A KR 20240075952 A KR20240075952 A KR 20240075952A KR 1020247013425 A KR1020247013425 A KR 1020247013425A KR 20247013425 A KR20247013425 A KR 20247013425A KR 20240075952 A KR20240075952 A KR 20240075952A
Authority
KR
South Korea
Prior art keywords
phenyl
amino
methyl
pyrrolo
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247013425A
Other languages
English (en)
Korean (ko)
Inventor
징위 후
샨레이 푸
얀차오 리오우
쯔숑 장
웨이보 장
샤오징 후
케빈 엑스 천
Original Assignee
3에이치 파머슈티컬즈 컴퍼니 리미티드
3에이치 (쑤저우) 파머슈티컬즈 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3에이치 파머슈티컬즈 컴퍼니 리미티드, 3에이치 (쑤저우) 파머슈티컬즈 컴퍼니 리미티드 filed Critical 3에이치 파머슈티컬즈 컴퍼니 리미티드
Publication of KR20240075952A publication Critical patent/KR20240075952A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247013425A 2021-09-23 2022-09-23 Fgfr 억제제 및 이의 사용 방법 Pending KR20240075952A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/119861 2021-09-23
CN2021119861 2021-09-23
CN2022096894 2022-06-02
CNPCT/CN2022/096894 2022-06-02
PCT/CN2022/121076 WO2023046117A1 (en) 2021-09-23 2022-09-23 Fgfr inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20240075952A true KR20240075952A (ko) 2024-05-30

Family

ID=85720119

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013425A Pending KR20240075952A (ko) 2021-09-23 2022-09-23 Fgfr 억제제 및 이의 사용 방법

Country Status (8)

Country Link
US (1) US20240383905A1 (https=)
EP (1) EP4405358A4 (https=)
JP (1) JP2024536858A (https=)
KR (1) KR20240075952A (https=)
CN (1) CN118043327A (https=)
AU (1) AU2022350571A1 (https=)
CA (1) CA3231948A1 (https=)
WO (1) WO2023046117A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240161599A (ko) * 2023-05-04 2024-11-12 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402161A (zh) * 2022-07-06 2024-01-16 上海科恩泰生物医药科技有限公司 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
CN115232147B (zh) * 2022-08-09 2023-10-13 南方科技大学 一种作为HIF-2α激动剂的杂环衍生物
CN120344533A (zh) * 2022-11-22 2025-07-18 海思科医药集团股份有限公司 一种嘧啶衍生物及其在医药上的应用
WO2024208315A1 (zh) * 2023-04-07 2024-10-10 中国医药研究开发中心有限公司 芳香杂环类化合物及其制备方法和医药用途
CN121263414A (zh) * 2023-05-26 2026-01-02 上海艾力斯医药科技股份有限公司 杂芳环类化合物、其药物组合物及其应用
CN121693505A (zh) * 2023-11-17 2026-03-17 上海齐鲁制药研究中心有限公司 含氮杂芳基衍生物、其制备方法及其在医药上的应用
WO2025149021A1 (zh) * 2024-01-10 2025-07-17 海思科医药集团股份有限公司 一种吡啶并吡咯衍生物及其在医药上的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
GB0031080D0 (en) * 2000-12-20 2001-01-31 Novartis Ag Organic compounds
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005061504A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof
DE102008052943A1 (de) * 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
CN105837576B (zh) * 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN108997380A (zh) * 2018-07-26 2018-12-14 长春海谱润斯科技有限公司 一种嘌呤化合物及其有机电致发光器件
WO2020231990A1 (en) * 2019-05-13 2020-11-19 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240161599A (ko) * 2023-05-04 2024-11-12 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
JP2024536858A (ja) 2024-10-08
AU2022350571A1 (en) 2024-05-09
CN118043327A (zh) 2024-05-14
EP4405358A1 (en) 2024-07-31
US20240383905A1 (en) 2024-11-21
WO2023046117A1 (en) 2023-03-30
CA3231948A1 (en) 2023-03-30
EP4405358A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
JP7005582B2 (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
KR20240075952A (ko) Fgfr 억제제 및 이의 사용 방법
CN115192577B (zh) Kras突变蛋白抑制剂
EP2857404B1 (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
CN106132950B (zh) 氨基吡啶类化合物和使用方法
JP5167291B2 (ja) ジヒドロピラゾロピリミジノン誘導体
TW202525800A (zh) Ｒａｓ抑制劑
AU2016366546B2 (en) Inhibitors of Bruton's tyrosine kinase and methods of their use
WO2018121228A1 (zh) 一种具有axl抑制活性的化合物及其制备和应用
WO2008081914A1 (ja) Ｐｌｋ１阻害剤としての新規アミノピリミジン誘導体
KR20230051528A (ko) 화합물, 조성물 및 방법
CN110818641B (zh) 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
WO2023006013A1 (zh) 新型parp7抑制剂及其应用
CN112513041B (zh) 三环化合物
TWI915634B (zh) Fgfr抑制劑及其使用方法
TW202400159A (zh) Fgfr抑制劑及其使用方法
HK40105619A (zh) 包括氮杂环丁烷环脲的rip1调节剂、其制备和用途
WO2025215153A1 (en) Prmt5 inhibitors
HK40110493A (zh) Fgfr抑制剂及其使用方法
HK1262758A1 (en) Aminopyridines compounds and methods of use
HK1230619A1 (en) Aminopyridines compounds and methods of use
HK1230619B (zh) 氨基吡啶類化合物和使用方法
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK1233627A1 (en) Serine/threonine kinase inhibitors
HK1233627A (en) Serine/threonine kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)